相关临床试验
633
179 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
86
13.6%
已完成
190
30.0%
Enrolling By Invitation
14
2.2%
尚未招募
79
12.5%
招募中
177
28.0%
暂停
4
0.6%
终止
17
2.7%
Unknown
64
10.1%
撤回
2
0.3%
暂无批准数据
- A Nature publication validates PLA2G2D as a mechanistically distinct immune checkpoint, identified independently by Apeximmune and Erasmus MC through computational and spatial proteogenomic approaches. - Apeximmune demonstrated that an enzyme-dead form of PLA2G2D retains potent immunosuppressive activity, revealing a non-enzymatic mechanism the field had previously overlooked. - Preclinical data show PLA2G2D blockade restores anti-tumor immunity in anti-PD-1-resistant models and potentiates anti-PD-1 activity in otherwise unresponsive tumors. - Apeximmune's first-in-class antibody AI-306 is in IND-enabling development, with GLP toxicology studies starting in late 2026 and an IND filing targeted for Q2 2027.
- The FAST III trial demonstrated that vessel fractional flow reserve (vFFR) guided revascularization was non-inferior to traditional pressure wire-based FFR in 2,211 patients with intermediate coronary lesions across 37 European centers. - Both treatment groups showed identical 7.5% rates of major adverse cardiac events at one year, with vFFR offering procedural advantages including shorter procedure times and fewer complications. - The angiography-based vFFR technology eliminates the need for pressure wires and hyperemic agents, potentially expanding access to physiologic lesion assessment while maintaining safety and efficacy. - Results published in the New England Journal of Medicine represent a significant milestone toward less invasive coronary assessment methods in clinical practice.
- Tonix Pharmaceuticals has dosed the first participant in a Phase 1 investigator-initiated study evaluating TNX-1900, an intranasal potentiated oxytocin formulation, for migraine and craniofacial pain treatment. - The study will assess TNX-1900's effect on trigeminal nerve-mediated vasodilation using a novel imaging technique called Laser Speckle Contrast Imaging to measure forehead blood flow responses. - TNX-1900 works through a distinct mechanism by blocking CGRP release at the trigeminal ganglion level, potentially offering advantages over existing CGRP inhibitors and triptans. - The drug targets approximately 1.2 billion migraine sufferers globally, including 39 million Americans, with a non-opioid approach that has no recognized addiction potential.
- Preliminary data from the DURIPANC Phase 2 trial shows 21% of metastatic pancreatic cancer patients achieved progression-free survival exceeding 6 months with rintatolimod plus durvalumab combination therapy. - The combination demonstrated a favorable safety profile with no significant toxicity in 14 enrolled patients who had previously received FOLFIRINOX chemotherapy. - Early survival data indicates 64% of patients achieved overall survival greater than 6 months, outperforming historical benchmarks in this aggressive disease setting. - The trial represents a collaboration between AIM ImmunoTech, AstraZeneca, and Erasmus Medical Center, targeting a patient population with limited treatment options.
- AIM ImmunoTech's Phase 2 DURIPANC study evaluating Ampligen combined with AstraZeneca's Imfinzi shows encouraging safety and efficacy signals in metastatic pancreatic cancer patients post-FOLFIRINOX treatment. - The combination therapy demonstrated no significant toxicity with 21% of patients achieving progression-free survival greater than 6 months and 64% of patients surviving beyond 6 months. - The study builds on previous monotherapy data from over 50 patients treated under compassionate use, representing a potential breakthrough in a disease with historically limited immunotherapy responsiveness. - Results suggest superior outcomes compared to historical data for maintenance or second-line immunotherapies in pancreatic cancer, a disease that kills over 500,000 people worldwide annually.
- The FDA granted Breakthrough Therapy Designation to Egetis Therapeutics' tiratricol in July 2025 for treating MCT8 deficiency, based on survival data showing significant improvement in treated versus untreated patients. - Egetis has submitted a pre-NDA meeting request to the FDA to discuss the contents and timing of the US NDA submission for tiratricol, with plans to initiate the submission during 2025. - The ReTRIACt study currently has 15 evaluable patients enrolled, and tiratricol has already received EU approval as Emcitate in February 2025 for MCT8 deficiency treatment. - MCT8 deficiency is a rare genetic disorder affecting fewer than 1,000 individuals globally with no previously approved therapies, representing a significant unmet medical need.
- The GREG initiative, a five-year €26.2 million public-private partnership, has launched to advance Real-World Evidence practices for medicines and medical devices evaluation across Europe. - Uniting 29 partner organizations from 15 countries, GREG aims to develop evidence-based guidance and tools to inform regulatory and Health Technology Assessment decision-making processes. - The European Society of Cardiology will lead patient engagement efforts, utilizing federated analysis methods to improve data collection on care quality and develop new treatment strategies for cardiovascular diseases.
- Children from socioeconomically disadvantaged backgrounds show more severe brain inflammation and tissue loss when diagnosed with multiple sclerosis, according to a new study published in Neurology. - Researchers found that parental smoking may significantly increase MS risk in genetically predisposed children, potentially triggering immune system dysfunction and brain changes visible on MRI scans. - These findings suggest that MS development may begin in childhood, highlighting the importance of early environmental interventions and supporting the growing evidence of Epstein-Barr virus as a potential MS trigger.
- Safety Committee grants approval for Phase 2 portion of AIM ImmunoTech's Phase 1b/2 trial evaluating Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer treatment. - The trial, conducted at Erasmus Medical Center in the Netherlands, addresses a critical unmet need in oncology, with pancreatic cancer claiming approximately 50,000 American lives annually. - The combination therapy aims to enhance immune system response through Ampligen's immune reprogramming properties alongside Imfinzi's checkpoint inhibition mechanism.
